Compare ADMA Biologics Inc (ADMA) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Colgate-Palmolive Company — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Colgate-Palmolive Company trades at $92.43 (market cap $73.59B). The key difference: Colgate-Palmolive Company is far larger — about 33.1× ADMA Biologics Inc's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CL | |
|---|---|---|
Market Cap | $2.22B | $73.59B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $99.14 |
52-Week Low | $7.60 | $74.98 |
Enterprise Value | $2.29B | $80.07B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
Colgate-Palmolive (CL) trades at $92.54, down 0.65% on the day, with neutral technical signals and strong fundamentals. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% revenue growth and margin expansion. Recent news highlights director share sales and mixed regional performance, particularly weakness in North America despite global strength.
CL offers stable dividend returns and consistent earnings but faces valuation concerns with a P/E of 36.34 and competitive pressures in key markets. Analyst consensus targets $99.10 with 42% buy ratings, suggesting moderate upside potential balanced against premium valuation and domestic market challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
